ImmunoPrecise’s Dutch Subsidiary U-Protein Express joins new biotech accelerator in Utrecht Science Park

Biotechnology company ImmunoPrecise Antibodies Ltd has announced that its Dutch subsidiary U-Protein Express BV is locating in the upcoming “Accelerator” facility, a state-of-the-art facility for innovative companies in the Life Sciences sector at Utrecht Science Park.

The company joins biotech firms Genmab and Merus that are also taking up home in the Accelerator. These biotech companies all aim to improve lives of patients by developing innovative cancer therapies. Valuable collaborations are key for this goal. The Accelerator endorses this ambition becoming a unique hub for collaboration within the Dutch LSH innovation ecosystem.

Connecting life sciences companies in the Netherlands

“We are happy to welcome U-Protein Express to Accelerator,” said Chiel van Dijen, Commercial Director of Kadans Science Partner. “Accelerator is designed to facilitate and connect Life Sciences companies, creating a tight international community within Utrecht Science Park. U-Protein Express is a great addition to the ecosystem and Accelerator will stimulate their growth ambitions.”

Boosting LSH research capacity in the Netherlands

Dr. Martin Hessing, General Manager of U-Protein Express, stated: “We are delighted to move our continuously expanding service activities towards the new building alongside important stakeholders such as Genmab and Merus. This will enable us to keep in pace with our growing contract research business as Accelerator will give us over three to four times the current capacity”.

Growing European demand for innovative biotechnology

“The investments we are making in our European operations are a strong reflection of ImmunoPrecise’s position in the marketplace and positive outlook for the future,” said Dr. Jennifer Bath, President and CEO. “The Accelerator provides state-of-the-art facilities that enable our talented team to respond to the increasing demand for our services and innovative technologies.”

About ImmunoPrecise Antibodies

ImmunoPrecise is an international, full-service, therapeutic antibody discovery company. The company’s discovery and development are conducted in Utrecht and Oss, the Netherlands (U-Protein Express and IPA Europe, respectively), and in Victoria, British Columbia (IPA Canada). The company operates globally to offer a continuum of superior antibody services, transforming the face of therapeutic discovery, by decreasing turnaround time and risk, and promoting clinical success.

Source: ImmunoPrecise Antibodies